fbpx Skip to main content

THURSDAY, Jan. 28, 2021 (HealthDay News) — For patients discharged after acute ischemic stroke (AIS), the risk for stroke-associated pneumonia (SAP) is reduced for those with psoriasis or other chronic inflammatory diseases, according to a study published in the April issue of the Journal of Stroke and Cerebrovascular Diseases.

Layne Dylla, M.D., Ph.D., from the University of Colorado School of Medicine in Aurora, and colleagues examined the correlation between chronic inflammatory diseases and SAP using data from the 2015 to 2017 National Inpatient Sample. Hospital discharges with a diagnosis of AIS were classified as having ulcerative colitis, Crohn disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, other chronic inflammatory diseases, multiple chronic inflammatory diseases, or none.

The researchers found that among AIS discharges, the risk for SAP was reduced among those with psoriasis or other chronic inflammatory diseases compared with those without psoriasis and other chronic inflammatory diseases, respectively (adjusted odds ratios [95 percent confidence intervals], 0.70 [0.63 to 0.99] and 0.64 [0.46 to 0.89], respectively). Reduced in-hospital mortality was seen in association with rheumatoid arthritis, psoriasis, and other chronic inflammatory diseases (adjusted odds ratios [95 percent confidence intervals], 0.89 [0.78 to 1.00], 0.77 [0.59 to 1.00], and 0.69 [0.50 to 0.94], respectively).

“This study identifies a variable association between individual chronic inflammatory diseases and stroke-associated pneumonia,” the authors write. “Specifically, psoriasis and other inflammatory spondyloarthropathies (ankylosing spondylitis, polymyalgia rheumatica) may be protective from stroke-associated pneumonia, whereas, these in addition to rheumatoid arthritis may be associated with decreased risk of in-hospital mortality.”

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Does Age Matter for Advanced Melanoma Treatments?

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More